Efficacy and Safety of Olezarsen in Hypertriglyceridemia: An Updated Meta‐Analysis of Randomised Controlled Trials
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70716 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Ahmed Emara und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Al-Azhar University, Cairo, Egypt. Hauptthemen laut MEDLINE: Hypertriglyceridemia, Oligonucleotides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
Aims
Hypertriglyceridemia is a common lipid disorder linked to residual cardiovascular risk and acute pancreatitis despite standard therapy. Olezarsen, an antisense oligonucleotide targeting apolipoprotein C‐III (ApoC‐III), offers a novel triglyceride‐lowering strategy. We performed an updated meta‐analysis to evaluate its efficacy and safety. Methods and Materials We performed a meta‐analysis of randomised controlled trials (RCTs) identified through PubMed, Cochrane, Scopus and Web of Science up to December 2025. Random‐effects models were used to pool mean percentage changes (MDs) and risk ratios (RRs) with 95% confidence intervals (CIs). PROSPERO ID: CRD420261279110.
Results
Six RCTs with 2676 participants were analysed. Olezarsen significantly reduced triglycerides at 50 mg (MD −46.61%, 95% CI −49.59 to −43.64) and 80 mg (MD −54.37%, 95% CI −61.26 to −47.48), both p < 0.0001. ApoC‐III was markedly reduced (50 mg: MD −63.51%, 95% CI −74.18 to −52.84; 80 mg: MD −66.88%, 95% CI −77.91 to −55.85; both p < 0.0001). Non‐HDL‐C also decreased significantly (50 mg: MD −21.41%, 95% CI −25.12 to −17.70; p < 0.0001; 80 mg: MD −25.28%, 95% CI −33.99 to −16.58; p = 0.001). LDL‐C increased modestly at 50 mg (MD 17.58%, 95% CI 0.24 to 34.93; p = 0.047). Olezarsen reduced acute pancreatitis risk (50 mg: RR 0.16, 95% CI 0.05–0.48; p = 0.001; 80 mg: RR 0.33, 95% CI 0.14–0.76; p = 0.009). Overall adverse events were comparable to placebo, while ALT/AST ≥ 3 × ULN increased with 80 mg (RR 2.56, 95% CI 1.20–5.44; p = 0.01).
Conclusions
Olezarsen provides substantial triglyceride reduction with favourable effects on atherogenic lipoproteins and a tolerable short‐term safety profile. Longer‐term trials are needed to confirm cardiovascular outcomes and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
- Clinical Research Department, El-Gomhoria General Hospital, MOHP, Alexandria, Egypt.
- Department of Medicine, An-Najah National University, Nablus, West Bank, Palestine.
- Kuwait Institute for Medical Specializations, Kuwait City, Kuwait.
- Department of Internal Medicine, King Hamad University Hospital, Busaiteen, Bahrain.
- Department of Medicine, Advocate Illinois Masonic Medical Center, Chicago, Illinois, USA.
ORCID-Profile: Ahmed Emara
Zitieren
APA
Emara, A., Mansour, A., Aboeldahab, H., Awashra, A., Abbas, O. F., Abdul-Hafez, H. A., Alsubaiei, A. A., AlSejari, N., Salman Saif, H., Shubietah, A., & Mhanna, M. (2026). Efficacy and Safety of Olezarsen in Hypertriglyceridemia: An Updated Meta‐Analysis of Randomised Controlled Trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70716
Vancouver
Emara A, Mansour A, Aboeldahab H, Awashra A, Abbas OF, Abdul-Hafez HA, et al. Efficacy and Safety of Olezarsen in Hypertriglyceridemia: An Updated Meta‐Analysis of Randomised Controlled Trials. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70716
BibTeX
@article{Emara2026,
author = {Emara, Ahmed and Mansour, Ahmed and Aboeldahab, Heba and Awashra, Ameer and Abbas, Omar F and Abdul-Hafez, Hamza A and Alsubaiei, Amal A and AlSejari, Najat and Salman Saif, Hamad and Shubietah, Abdalhakim and Mhanna, Mohammed},
title = {Efficacy and Safety of Olezarsen in Hypertriglyceridemia: An Updated Meta‐Analysis of Randomised Controlled Trials},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70716}
}
EUVIMED